JP2021512652A5 - - Google Patents

Download PDF

Info

Publication number
JP2021512652A5
JP2021512652A5 JP2020565006A JP2020565006A JP2021512652A5 JP 2021512652 A5 JP2021512652 A5 JP 2021512652A5 JP 2020565006 A JP2020565006 A JP 2020565006A JP 2020565006 A JP2020565006 A JP 2020565006A JP 2021512652 A5 JP2021512652 A5 JP 2021512652A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512652A (ja
JP7333523B2 (ja
Filing date
Publication date
Priority claimed from CN201810144817.4A external-priority patent/CN110144008B/zh
Application filed filed Critical
Publication of JP2021512652A publication Critical patent/JP2021512652A/ja
Publication of JP2021512652A5 publication Critical patent/JP2021512652A5/ja
Application granted granted Critical
Publication of JP7333523B2 publication Critical patent/JP7333523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565006A 2018-02-12 2019-02-11 Cd38タンパク質抗体及びその使用 Active JP7333523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810144817.4A CN110144008B (zh) 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用
CN201810144817.4 2018-02-12
PCT/CN2019/074806 WO2019154421A1 (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Publications (3)

Publication Number Publication Date
JP2021512652A JP2021512652A (ja) 2021-05-20
JP2021512652A5 true JP2021512652A5 (https=) 2021-07-01
JP7333523B2 JP7333523B2 (ja) 2023-08-25

Family

ID=67547850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565006A Active JP7333523B2 (ja) 2018-02-12 2019-02-11 Cd38タンパク質抗体及びその使用

Country Status (11)

Country Link
US (1) US11713357B2 (https=)
EP (1) EP3753955A4 (https=)
JP (1) JP7333523B2 (https=)
KR (1) KR102770962B1 (https=)
CN (3) CN110144008B (https=)
AU (1) AU2019218518B2 (https=)
BR (1) BR112020016271A2 (https=)
CA (1) CA3091492C (https=)
SG (1) SG11202007443XA (https=)
TW (1) TWI818952B (https=)
WO (1) WO2019154421A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技(成都)有限公司 药物组合物及其制备方法和应用
CN114075283A (zh) * 2020-08-12 2022-02-22 三生国健药业(上海)股份有限公司 结合人cd38的抗体、其制备方法和用途
CN114075285B (zh) * 2020-08-20 2023-05-30 瑞阳(苏州)生物科技有限公司 抗人cd38人源化单克隆抗体及其应用
CN116547307A (zh) * 2021-12-03 2023-08-04 南京维立志博生物科技有限公司 结合cd38的抗体及其用途
WO2024183634A1 (en) * 2023-03-09 2024-09-12 Norroy Bioscience Co., Ltd. Radiolabeled antibody conjugates and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
RU2402568C2 (ru) 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
KR20140066259A (ko) * 2004-02-06 2014-05-30 모르포시스 아게 항-cd38 인간 항체 및 그의 용도
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー/エス 多発性骨髄腫の治療のためのcd38に対する抗体
CA2625681C (en) * 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2009301580B2 (en) * 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HUE054271T2 (hu) 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése
EA201792546A1 (ru) * 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
CA3004152C (en) * 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
JP7679196B2 (ja) 2017-06-08 2025-05-19 ブラック ベルト セラピューティクス リミテッド Cd38調節抗体
CN110997722B (zh) * 2017-06-08 2023-09-26 黑带医疗有限公司 Cd38调节抗体

Similar Documents

Publication Publication Date Title
JP2024522360A5 (https=)
JP2021512652A5 (https=)
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
JP2021514664A5 (https=)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2021534762A5 (https=)
JP2021516057A5 (https=)
JP2021526022A5 (https=)
JP2021500916A5 (https=)
JP2022533538A5 (https=)
JP2017535257A5 (https=)
JP2017149720A5 (https=)
IL259036A (en) asct2-specific binding molecules and their uses
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2020522280A5 (https=)
JP2017512759A5 (https=)
JP2021517459A5 (https=)
RU2012103212A (ru) Tlr3 связывающие агенты
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2021528047A5 (https=)
JP2020522281A5 (https=)
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2019534892A5 (https=)
JP2020515277A5 (https=)
JP2023506834A5 (https=)